You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Vertical GaN Substrates

    SBC: SIXPOINT MATERIALS, INC.            Topic: N/A

    SixPoint Materials will create low-cost, high-quality vertical gallium nitride (GaN) substrates using a multi-phase production approach that employs both hydride vapor phase epitaxy (HVPE) technology and ammonothermal growth techniques to lower costs and maintain crystal quality. Substrates are thin wafers of semiconducting material needed for power devices. In its two-phase project, SixPoint Mate ...

    STTR Phase I 2014 Department of EnergyARPA-E
  2. Vertical GaN Substrates

    SBC: SIXPOINT MATERIALS, INC.            Topic: DEFOA0000941

    SixPoint Materials will create low-cost, high-quality vertical gallium nitride (GaN) substrates using a multi-phase production approach that employs both hydride vapor phase epitaxy (HVPE) technology and ammonothermal growth techniques to lower costs and maintain crystal quality. Substrates are thin wafers of semiconducting material needed for power devices. In its two-phase project, SixPoint Mate ...

    STTR Phase II 2014 Department of EnergyARPA-E
  3. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  4. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  5. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...

    STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government